{
  "id": 28133,
  "title": "New HIV Frontier: The Fight to Access Long-Acting Prevention Drugs",
  "url": "https://urgent.news/2026/07/29/new-hiv-frontier-the-fight-to-access-long-acting-prevention-drugs",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-07-29T01:03:49.000Z",
  "source": {
    "name": "Health Policy Watch",
    "slug": "health-policy-watch",
    "url": "https://healthpolicy-watch.news/brazil-pushes-for-inclusion-in-pharma-deals/"
  },
  "original_language": "en",
  "account": null,
  "summary": "RIO DE JANEIRO – News that an antiretroviral drug injected twice a year had prevented almost all HIV infection in trials electrified the HIV sector two years ago – but access to Gilead’s lenacapavir has been slow, particularly for countries in Latin America. Brazil, which faces significant HIV transmission in certain groups, has been routinely […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}